Search results
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Notwithstanding ongoing confusion over the concepts of...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
Nonspecific low back pain is diagnosed by ruling out other...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
Scalp hair regrowth is associated with improvements in...
- Clinical Problem-Solving Looking Back L. Glick and Others
On examination, the temperature was 36.1°C, the blood...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Accelerating COVID-19 Therapeutic Interventions and Vaccines...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
14 gru 2022 · Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Naggie S. Ivermectin for treatment of mild-to-moderate COVID-19 in the outpatient setting: a...
23 lip 2022 · Ravikirti, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, Manjhi PK, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India.
13 maj 2021 · BENGALURU, May 13 (Reuters) - At least two Indian states have said they plan to dose their populations with the anti-parasitic drug ivermectin to protect against severe COVID-19 infections...
We found 14 studies with 1678 participants that investigated ivermectin compared to no treatment, placebo, or usual care. For treatment, there were nine studies of people with moderate COVID-19 in hospital and four of outpatients with mild COVID-19.
Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020.
1 sie 2024 · Five databases were searched until October 17, 2023, for randomized controlled trials (RCTs) in adult patients with COVID-19 treated with ivermectin against standard of care (SoC), placebo, or active drug. Primary outcomes were hospitalization, all-cause mortality, and adverse events (AEs).
